Drug Classification · Questions 1–3
Identify the pharmacological class or categorical label for each drug or receptor. Vocabulary preparation is sufficient to answer every question in this section.
Question 1
Aspirin is classified as serving which goal of antianginal patient management?
Correct Answer
A) Cardioprotection
Rationale
Aspirin is classified as a cardioprotective agent, reducing the risk of myocardial infarction and death rather than directly controlling anginal symptoms.
Question 2
A statin is classified as serving which goal of antianginal patient management?
Correct Answer
B) Cardioprotection
Rationale
A statin is classified as a cardioprotective agent, part of background therapy that reduces the risk of myocardial infarction and death regardless of which antianginal drugs are chosen for symptom relief.
Question 3
Beta-blockers are classified as serving which goal profile among antianginal drug classes?
Correct Answer
C) Both symptom control and cardioprotection
Rationale
Beta-blockers are classified as the one antianginal class that serves both roles, since beyond their anti-ischemic effect they also carry a proven mortality benefit after myocardial infarction.
Core Pharmacology · Questions 4–11
Apply your understanding of drug mechanisms, pharmacokinetics, and adverse effects. Each question requires one reasoning step.
Question 4
Why are symptom control and cardioprotection treated as two separate prescribing decisions in a patient with stable angina?
Correct Answer
A) Most antianginal drugs treat symptoms without changing the underlying risk of myocardial infarction or death
Rationale
Most antianginal drugs treat symptoms without changing the underlying risk of myocardial infarction or death, which is why every patient with stable angina receives cardioprotective background therapy such as aspirin and a statin regardless of which specific antianginal drugs are chosen for symptom relief.
Question 5
Why is a beta-blocker typically the starting agent for stable exertional angina?
Correct Answer
C) It addresses two of the four hemodynamic levers at once and, for many patients, also provides cardioprotection
Rationale
A beta-blocker is typically the starting point because it addresses two of the four hemodynamic levers, heart rate and contractility, at once and, for many patients, also provides cardioprotection beyond its anti-ischemic effect.
Question 6
Why is a long-acting dihydropyridine calcium channel blocker the preferred second agent when a beta-blocker alone provides insufficient symptom control?
Correct Answer
B) The beta-blocker blunts the reflex tachycardia the dihydropyridine would otherwise trigger, and neither drug compounds the other's effect on cardiac conduction
Rationale
A long-acting dihydropyridine is the preferred second agent because the beta-blocker blunts the reflex tachycardia the calcium channel blocker would otherwise trigger, and neither drug compounds the other's effect on cardiac conduction, unlike the combination with a non-dihydropyridine.
Question 7
Why do ranolazine and ivabradine become attractive next steps when symptoms persist despite a beta-blocker and dihydropyridine combination?
Correct Answer
D) They add anti-ischemic benefit without compounding the bradycardia or hypotension that limit further dosing of the hemodynamic agents already in use
Rationale
When symptoms persist despite a beta-blocker and dihydropyridine combination, ranolazine and ivabradine become attractive next steps precisely because they add anti-ischemic benefit without compounding bradycardia or hypotension, the dose-limiting problems of the hemodynamic agents already in use.
Question 8
According to the general organizing principle for antianginal combinations, why does pairing a beta-blocker with a non-dihydropyridine calcium channel blocker violate good combination logic?
Correct Answer
A) It suppresses the same hemodynamic target, the sinoatrial and atrioventricular nodes, twice rather than adding a drug that targets a new mechanism
Rationale
Every combination decision in this chapter follows the same underlying logic: add a drug that targets a hemodynamic lever or mechanism not already addressed by the patient's current regimen, while avoiding combinations that suppress the same target twice, such as the beta-blocker plus non-dihydropyridine combination.
Question 9
Why are calcium channel blockers, rather than beta-blockers, first-line therapy for vasospastic angina, reversing the typical stable angina sequence?
Correct Answer
C) Vasospastic angina is a pure supply problem driven by spasm, so calcium channel blockers directly counteract the hyperreactivity, while beta-blockers risk unopposed alpha-1 vasoconstriction
Rationale
Because vasospastic angina is a pure supply problem driven by coronary artery spasm rather than a demand problem, calcium channel blockers directly counteract the calcium-mediated smooth muscle hyperreactivity responsible for spasm, while beta-blockers remain contraindicated since unopposed alpha-1 vasoconstriction can precipitate or worsen the spasm.
Question 10
Why has no single drug class demonstrated clear superiority for treating microvascular angina?
Correct Answer
B) The underlying physiology of microvascular dysfunction is less uniform and less completely understood than in the other two angina subtypes
Rationale
Because the underlying physiology of microvascular angina is less uniform and less completely understood than in stable or vasospastic angina, no single drug class has demonstrated clear superiority, and management typically involves a trial of beta-blockers, calcium channel blockers, or both.
Question 11
Why can the same drug class be first-line therapy in one angina subtype and contraindicated in another?
Correct Answer
D) The three angina subtypes arise from different underlying physiology, and the appropriate drug strategy follows directly from that physiology
Rationale
Angina is not a single disease with a single treatment algorithm. The three subtypes, stable, vasospastic, and microvascular, arise from different underlying physiology, and the appropriate drug strategy follows directly from that physiology, which is why no single antianginal algorithm applies to every patient with chest pain.
Clinical Correlations · Questions 12–15
Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.
Question 12
A 59-year-old man is newly diagnosed with stable exertional angina. His physician starts a beta-blocker for symptom control, and also starts aspirin and a statin. He asks why he needs three medications when his only complaint is chest discomfort with exertion. Which of the following best explains the reasoning behind adding aspirin and a statin?
Correct Answer
B) Symptom control and cardioprotection are separate goals, and aspirin and a statin reduce his risk of myocardial infarction and death independent of which antianginal drug controls his symptoms
Rationale
Most antianginal drugs treat symptoms without changing the underlying risk of myocardial infarction or death. Every patient with stable angina receives cardioprotective background therapy such as aspirin and a statin regardless of which specific antianginal drugs are chosen for symptom relief, since the two prescribing decisions answer two different clinical questions.
Question 13
A 63-year-old woman with stable angina continues to have symptoms despite an adequate dose of metoprolol. Her physician adds amlodipine rather than diltiazem as the second agent. Which of the following best explains why a dihydropyridine is the preferred choice in this setting?
Correct Answer
C) Amlodipine acts on a complementary hemodynamic target without adding to the atrioventricular conduction suppression a non-dihydropyridine would add to the beta-blocker
Rationale
A long-acting dihydropyridine is the preferred second agent because the beta-blocker blunts the reflex tachycardia the dihydropyridine would otherwise trigger, and neither drug compounds the other's effect on cardiac conduction, unlike the beta-blocker plus non-dihydropyridine combination, which is avoided due to additive suppression of the same conduction system.
Question 14
A 47-year-old woman has recurrent chest pain at rest, predominantly in the early morning, with transient ST-segment elevation during episodes that resolves between attacks. Her physician starts diltiazem rather than a beta-blocker. Which of the following best explains why this reversed prescribing sequence, compared with typical stable angina management, is appropriate for her?
Correct Answer
A) Her presentation is vasospastic angina, in which calcium channel blockers directly counteract the spasm while beta-blockers risk unopposed alpha-1 vasoconstriction
Rationale
This presentation describes vasospastic angina. Because it is a pure supply problem driven by coronary spasm rather than a demand problem, calcium channel blockers are first-line therapy, directly counteracting the calcium-mediated hyperreactivity responsible for spasm, while beta-blockers remain contraindicated due to the risk of unopposed alpha-1 vasoconstriction.
Question 15
A 56-year-old woman has typical anginal symptoms with a positive stress test, but coronary angiography shows no significant obstruction in the major epicardial arteries. A trial of a beta-blocker does not adequately control her symptoms. Her physician switches her to a trial of a calcium channel blocker instead of escalating the beta-blocker dose further. Which of the following best explains this approach?
Correct Answer
D) No single drug class has demonstrated clear superiority in microvascular angina, since the underlying physiology is less uniform and less completely understood than in the other subtypes
Rationale
This presentation describes microvascular angina. Because the underlying physiology is less uniform and less completely understood than in stable or vasospastic angina, no single drug class has demonstrated clear superiority, and management typically involves a trial of beta-blockers, calcium channel blockers, or both, with response that varies between patients.